Health care expenditures linked to the use of targeted therapies and diagnostic tests for cancer patients;Tests diagnostiques et thérapies ciblées en cancérologie Enjeux économiques

Medecine/Sciences

Volumn 28, Issue SPEC. ISSUE 1, 2012, Pages 19-23

  Marino, Patricia ^a,b,c   Bertucci, François ^a,c   Gonçalves, Anthony ^a,c   Seror, Valérie ^b,c  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIV   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST TUMOR; CARCINOMA; EARLY DIAGNOSIS; ECONOMICS; EXPERIMENTAL THERAPY; FEMALE; GENETICS; GENOMICS; HEALTH CARE COST; HUMAN; METHODOLOGY; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; NEOPLASM; REVIEW;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA; EARLY DETECTION OF CANCER; FEMALE; GENOMICS; HEALTH EXPENDITURES; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR TARGETED THERAPY; NEOPLASMS; THERAPIES, INVESTIGATIONAL;

EID: 84860860581     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/201228s106     Document Type: Review

References (22)

1. L'Horty Y, Quinet A, Rupprecht F. Expliquer la croissance des dépenses de santé : Le rôle du niveau de vie et du progrès technique. Économie et Prévision 1997 ; 129-130 : 257-68.
2. Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011 ; 103 : 117-28.
3. Situation de la chimiothérapie des cancers en 2010. Collection Rapports et synthèses. Boulogne-Billancourt : INCa, 2010.
4. Sobrero A, Bruzzi P. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. J Clin Oncol 2009 ; 27 : 5868-73.
5. Cohn DE, Kim KH, Resnick KE, et al. At what cost does a potential survival advantage of Bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 2009 ; 29 : 1247-51.
6. Hensley ML. Big costs for little gain in ovarian cancer. J Clin Oncol 2011 ; 29 : 1230-2.
7. Munro AJ, Niblock PG. Cancer research in the global village. Lancet 2010 ; 376 : 659-60.
8. Jackson DB, Sood AK. Personalized cancer medicine-advances and socioeconomic challenges. Nat Rev Clin Oncol 2011 ; 8 : 735-41.
9. Fojo T, Grady C. How much is life worth: Cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009 ; 101 :1044-8.
10. Meropol NJ, Schrag D, Smith TJ, et al. American society of clinical oncology guidance statement: The cost of cancer care. J Clin Oncol 2009 ; 27 : 3868-74.
11. Les tests de génétique moléculaire pour l'accès aux thérapies ciblées. Collection Rapports et synthèses. Boulogne-Billancourt : INCa, 2010.
12. De Lima Lopes G Jr, Segel JE, Tan DS, et al. Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer 2011 ; 26 juillet. doi : 10.1002/cncr.26372.
13. Blank PR, Moch H, Szucs TD, Schwenkglenks M. KRAS and BRAF mutation analysis in metastatic colorectal cancer: A cost-effectiveness analysis from a Swiss perspective. Clin Cancer Res 2011 ; 17 : 6338-46.
14. Shankaran V, Bentrem DJ, Mulcahy MF, et al. Economic implications of KRAS testing in metastatic colorectal cancer. San Francisco, CA : Gastrointestinal Cancers Symposium, January 15-17, 2009.
15. Van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002 ; 415 : 530-6. (Pubitemid 34130608)
16. Van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002 ; 347 : 1999-2009. (Pubitemid 35461656)
17. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004 ; 351 : 2817-26. (Pubitemid 40051905)
18. Bertucci F, Borie N, Roché H, et al. Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2011 ; 127 : 363-73.
19. Marino P, Siani C, Bertucci F, et al. Economic issues involved in integrating genomic testing into clinical care: The case of genomic testing to guide decision-making about chemotherapy for breast cancer patients. Breast Cancer Res Treat 2011 ; 129 : 401-9.
20. Seror V, Elasri K, Avenel E. Premières applications de la pharmacogénomique en oncologie : Stratégies industrielles et enjeux de régulation publique. Revue d'Économie Industrielle 2007 ; 120 : 235-52.
21. Gabszewicz J, Sonnac N, Wauthy X. On price competition with complementary goods. Economics Letters 2001 ; 70 : 431-9.
22. Bertucci F, Birnbaum D. Génomique et recherche clinique en cancérologie mammaire. Med Sci (Paris) 2012 ; 28 (Suppl 1) : 14-8.